2.14
price up icon4.90%   0.10
after-market After Hours: 2.14
loading
Phio Pharmaceuticals Corp stock is traded at $2.14, with a volume of 213.76K. It is up +4.90% in the last 24 hours and up +65.89% over the past month. Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.04
Open:
$2.03
24h Volume:
213.76K
Relative Volume:
0.07
Market Cap:
$13.52M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.2624
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-24.38%
1M Performance:
+65.89%
6M Performance:
-28.90%
1Y Performance:
-65.14%
1-Day Range:
Value
$2.01
$2.14
1-Week Range:
Value
$1.97
$2.91
52-Week Range:
Value
$0.9657
$9.79

Phio Pharmaceuticals Corp Stock (PHIO) Company Profile

Name
Name
Phio Pharmaceuticals Corp
Name
Phone
(508) 767-3861
Name
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Name
Employee
5
Name
Twitter
@phio_pharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PHIO's Discussions on Twitter

Compare PHIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PHIO
Phio Pharmaceuticals Corp
2.14 13.52M 0 -11.66M -11.09M -8.156
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-05-20 Initiated H.C. Wainwright Buy

Phio Pharmaceuticals Corp Stock (PHIO) Latest News

pulisher
Apr 23, 2025

Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister

Apr 23, 2025
pulisher
Apr 23, 2025

Best Momentum Stocks to Buy for April 23rd - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts

Apr 23, 2025
pulisher
Apr 22, 2025

Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Phio Pharmaceuticals Corp (PHIO) deserves closer scrutiny - uspostnews.com

Apr 22, 2025
pulisher
Apr 14, 2025

Investors’ Faith in Phio Pharmaceuticals Corp (PHIO) could reap rewards if they hold on for the long haul - uspostnews.com

Apr 14, 2025
pulisher
Apr 13, 2025

Contrasting Phio Pharmaceuticals (NASDAQ:PHIO) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) - Defense World

Apr 13, 2025
pulisher
Apr 11, 2025

Equities Analysts Offer Predictions for PHIO FY2025 Earnings - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

3 Penny Stocks to Watch Now, 4/10/25 - TipRanks

Apr 10, 2025
pulisher
Apr 09, 2025

Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled - MSN

Apr 09, 2025
pulisher
Apr 09, 2025

Phio advances skin cancer treatment with successful trial By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

This Biotech Is Ripping Following Phase 1b Trial Announcement - The Globe and Mail

Apr 09, 2025
pulisher
Apr 09, 2025

Crude Oil Down 4%; Neogen Shares Plunge After Q3 ResultsBloom Energy (NYSE:BE), Neogen (NASDAQ:NEOG) - Benzinga

Apr 09, 2025
pulisher
Apr 09, 2025

Phio Pharmaceuticals Advances PH-762 Cancer Treatment in Phase 1 - GuruFocus

Apr 09, 2025
pulisher
Apr 09, 2025

PHIO Advances PH-762 in Phase 1b Clinical Trial for Skin Cancers - GuruFocus

Apr 09, 2025
pulisher
Apr 09, 2025

Is Phio’s Surge Sustainable? - timothysykes.com

Apr 09, 2025
pulisher
Apr 09, 2025

Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

Phio advances skin cancer treatment with successful trial - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Apr 09, 2025
pulisher
Apr 09, 2025

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort - Newsfile

Apr 09, 2025
pulisher
Apr 09, 2025

Breakthrough in Skin Cancer Trial: PH-762 Shows 100% Tumor Clearance as Study Advances - Stock Titan

Apr 09, 2025
pulisher
Apr 09, 2025

Phio stock hits 52-week low at $0.99 amid sharp annual decline - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

Phio Pharmaceuticals’ (PHIO) Buy Rating Reaffirmed at HC Wainwright - Defense World

Apr 09, 2025
pulisher
Apr 08, 2025

Phio stock hits 52-week low at $0.99 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 - Investing.com Australia

Apr 08, 2025
pulisher
Apr 08, 2025

H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 03, 2025

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894 - Quantisnow

Apr 03, 2025
pulisher
Apr 03, 2025

3 Reasons to Sell PLCE and 1 Stock to Buy Instead - The Globe and Mail

Apr 03, 2025
pulisher
Apr 03, 2025

Groundbreaking Cancer Treatment Data: Phio's Dual Immunotherapy Candidates Show Promise - Stock Titan

Apr 03, 2025
pulisher
Apr 01, 2025

Phio stock hits 52-week low at $1.22 amid sharp annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Phio stock hits 52-week low at $1.22 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Phio Pharmaceuticals Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Virtu Financial LLC Makes New Investment in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Phio's Cancer Drug Shows Complete Response as Company Slashes Losses by 33% - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Phio Pharmaceuticals Corp. (PHIO) reports earnings - qz.com

Mar 31, 2025
pulisher
Mar 31, 2025

Phio Pharmaceuticals (PHIO) Expected to Announce Earnings on Monday - Defense World

Mar 31, 2025
pulisher
Mar 19, 2025

PHIO PHARMACEUTICALS CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 19, 2025
pulisher
Mar 12, 2025

PHIOPhio Pharmaceuticals Corp Latest Stock News & Market Updates - Stock Titan

Mar 12, 2025
pulisher
Mar 10, 2025

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

Phio Reports 50% Complete Response Rate in Skin Cancer Trial - StockTitan

Mar 10, 2025
pulisher
Mar 05, 2025

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study - Newsfile

Mar 05, 2025
pulisher
Mar 04, 2025

PHIO stock touches 52-week low at $1.25 amid sharp annual decline - Investing.com Australia

Mar 04, 2025
pulisher
Feb 28, 2025

Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated - MSN

Feb 28, 2025
pulisher
Feb 26, 2025

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile

Feb 26, 2025

Phio Pharmaceuticals Corp Stock (PHIO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Cap:     |  Volume (24h):